Department of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet University, Istanbul, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Prof. Dr. Suleyman Yalçın, Goztepe City Hospital, Istanbul, Turkey.
Expert Rev Vaccines. 2022 Feb;21(2):249-252. doi: 10.1080/14760584.2022.2012457. Epub 2021 Dec 7.
Durability of immune response by the COVID-19 natural infection and the necessity of vaccines in recovered patients are important inquiries for the healthcare provider.
Here, we investigated the characteristics and the rate of cases with reinfection that have been admitted to our tertiary hospital.
A total of 119985 patients were applied between March 2020 and May 2021. Of these patients, 32607 (27%, 32,607/119985) tested positive. A total of 27 (0.08%, 27/32607) patients were found to be reinfected beyond 90 days. Only one of these reinfected patients (0.003, 1/32607) had novel COVID-19 pneumonia and was hospitalized for the second time. Other 26 reinfected patients were followed up as outpatients.
COVID-19 reinfection is extremely rare. However, the reinfection may be severe in patients with immune deficiency. Healthcare providers may prioritize uninfected and immune-compromised patients for vaccination.
COVID-19 自然感染的免疫反应持久性以及康复患者接种疫苗的必要性是医疗保健提供者关注的重要问题。
在这里，我们调查了在我们的三级医院住院的已感染和再次感染病例的特征和比例。
2020 年 3 月至 2021 年 5 月期间共收治了 119985 例患者。这些患者中，32607 例（27%，32607/119985）检测呈阳性。共有 27 例（0.08%，27/32607）患者在 90 天后被发现再次感染。在这些再次感染的患者中，只有 1 例（0.003，1/32607）为新型 COVID-19 肺炎，并因第二次住院。其他 26 例再次感染的患者作为门诊患者进行了随访。
COVID-19 的再次感染极为罕见。然而，免疫缺陷患者的再次感染可能较为严重。医疗保健提供者可能会优先为未感染和免疫功能低下的患者接种疫苗。
